Guggenheim Initiates Retension Pharmaceuticals at Buy With $55 Target
Guggenheim initiated coverage at Buy and set a $55 price target. The target implies 384.2% upside from the Oct. 30 close of $11.36.
Guggenheim initiated coverage at Buy and set a $55 price target. The target implies 384.2% upside from the Oct. 30 close of $11.36.